DCK and ovarian carcinoma: Deficiency of the activating enzyme DCK led to acquired gemcitabine resistance in a human ovarian carcinoma cell line exposed to increasing levels of gemcitabine in vitro19 and patients with pancreatic cancer who express low levels of DCK have significantly poorer overall survival than those with high levels20.